Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03878069
Other study ID # CLI-06814AA1-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 25, 2019
Est. completion date January 18, 2023

Study information

Verified date April 2023
Source Chiesi Farmaceutici S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This registry is conducted in patients with adenosine deaminase severe combined immune deficiency (ADA-SCID) treated with Revcovi™ to collect periodic clinical and biochemical data on safety and dose adjustment.


Description:

Patients with ADA-SCID who require treatment with Revcovi as Enzyme Replacement Therapy (ERT) will be followed until the last enrolled patient has reached a minimum of 24 months of Revcovi treatment or until undergoing HSCT or HSCGT, whichever occurs first. Patients undergoing HSCT or HSC-GT will be followed one month after last Revcovi dose and again at six months to assess adverse events (AEs) and survival. Throughout the duration of the study, patients will be assessed continually for AEs. Patients/Parents/Caregivers will self-administer weekly intramuscular (IM) dose(s) of Revcovi and will be followed according to the Suggested Schedule of Assessments for trough dAXP and ADA activity. Treatment dosing and monitoring will be individualized per provider and patient characteristics in adherence with each study sites' standards of care. Patients in the Phase 3 Revcovi™ study (STP-2279-002) will be given the opportunity to enroll in this registry study and proceed to the Treatment Month 6 Visit per the Suggested Schedule of Assessments for Adagen-Transitioning Patients.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date January 18, 2023
Est. primary completion date January 18, 2023
Accepts healthy volunteers No
Gender All
Age group 0 Months to 65 Years
Eligibility Inclusion Criteria: - Patients currently receiving chronic ERT with Adagen® and transitioned/transitioning to Revcovi; - Infants diagnosed via newborn screening and definitive testing for ADA deficiency prescribed Revcovi; - Patients receiving Revcovi while preparing for Hematopoietic Stem Cell Transplant (HSCT) or Hematopoietic Stem Cell Gene Therapy (HSCGT) - Patients who decline, are ineligible or do not respond to HSCT or HSC-GT and resume/start Revcovi. Exclusion Criteria: - Any condition that, in the opinion of the Investigator, makes the patient unsuitable for the study.

Study Design


Intervention

Biological:
elapegademase-lvlr
Patients transitioning from Adagen: For patients currently receiving Adagen at = 30 U/kg/wk or an unknown Adagen dose, the suggested dosage of Revcovi is 0.2 mg/kg/wk IM. For patients currently receiving Adagen at > 30 U/kg/wk the suggested equivalent Revcovi dosage (mg/kg/wk) is the Adagen dosage in U/kg/wk divided by 150. At the investigator's discretion, the total weekly dose may be divided and administered in multiple IM injections, increased by 0.033 mg/kg/wk if trough ADA activity is < 30 mmol/hr/L, dAXP is > 0.02 mmol/L, and/or the immune reconstitution is inadequate. Adagen-naïve patients: The suggested starting Revcovi dosage is 0.2 mg/kg twice weekly IM based on ideal body weight, for a minimum of 12 to 24 weeks until immune reconstitution is achieved. At the investigator's discretion, the dosage may be gradually increased to maintain trough ADA activity > 30 mmol/hr/L, dAXP < 0.02 mmol/L, and/or to maintain adequate immune reconstitution.

Locations

Country Name City State
United States UBMD Pediatrics Outpatient Center Buffalo New York
United States Duke University Hospital Durham North Carolina
United States Penn State Children's Hospital Hershey Pennsylvania
United States University of California Los Angeles Los Angeles California
United States Le Bonheur Children's Hospital Memphis Tennessee
United States Children's Minnesota Minneapolis Minnesota
United States Childrens Hospital of New Orleans New Orleans Louisiana
United States UPMC Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States St. Louis Children's Hospital - Washington University School of Medicine Saint Louis Missouri
United States University of South Florida Allergy Immunology Clinic Saint Petersburg Florida
United States Allergy & Asthma Medical Group and Research Center, A P.C. San Diego California
United States UCSF - University of California San Francisco California
United States Seattle Children's Seattle Washington
United States Children's National Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Chiesi Farmaceutici S.p.A.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Deoxyadenosine nucleotides (dAXP) activity Total trough erythrocyte dAXP activity Month 24
Primary ADA activity Trough plasma ADA activity Month 24
Secondary Immune status (SSA/PI) Absolute lymphocyte count and subset B, T, and NK analysis.
Immunoglobulin (Ig) concentrations (IgG, IgA, and IgM).
Measurement of immune response at Investigator discretion.
Month 24
Secondary Clinical status Infections (clinically or microbiologically documented) Incidence and duration of hospitalizations Growth for patients < 18 years old Overall survival through the end of study Month 24
Secondary Safety assessed by determining adverse events (AEs), serious adverse events (SAEs) Assessed by determining adverse events (AEs), serious adverse events (SAEs), clinical signs and symptoms from physical examinations, and laboratory examinations Month 24
See also
  Status Clinical Trial Phase
Completed NCT00006335 - Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID N/A
Not yet recruiting NCT02231983 - Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China N/A
Active, not recruiting NCT03597594 - Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Phase 1/Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00001255 - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study N/A
Recruiting NCT05651113 - The Experience of Screening for SCID
Completed NCT00794508 - MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Phase 2
Recruiting NCT03538899 - Autologous Gene Therapy for Artemis-Deficient SCID Phase 1/Phase 2
Recruiting NCT05298930 - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00845416 - Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Recruiting NCT01019876 - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Withdrawn NCT02177760 - Sirolimus Prophylaxis for aGVHD in TME SCID Phase 2
Recruiting NCT00695279 - Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Completed NCT01420627 - EZN-2279 in Patients With ADA-SCID Phase 3
Terminated NCT02127892 - SCID Bu/Flu/ATG Study With T Cell Depletion Phase 1/Phase 2
Completed NCT04246840 - Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
Completed NCT01529827 - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2